- 全部删除
您的购物车当前为空
PD-1/PD-L1-IN-10 是一种口服有效的PD-1/PD-L1抑制剂 (IC50值为2.7 nM),显示出抗肿瘤活性。


为众多的药物研发团队赋能,
让新药发现更简单!
PD-1/PD-L1-IN-10 是一种口服有效的PD-1/PD-L1抑制剂 (IC50值为2.7 nM),显示出抗肿瘤活性。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 456 | In stock | |
| 5 mg | ¥ 996 | In stock | |
| 10 mg | ¥ 1,730 | In stock | |
| 25 mg | ¥ 2,930 | In stock | |
| 50 mg | ¥ 4,260 | In stock | |
| 100 mg | ¥ 5,920 | In stock | |
| 200 mg | ¥ 8,130 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,160 | In stock |
PD-1/PD-L1-IN-10 相关产品
| 产品描述 | PD-1/PD-L1-IN-10 is an orally available PD-1/PD-L1 inhibitor (IC50 value of 2.7 nM) that shows anti-tumor activity. |
| 靶点活性 | PD-1/PD-L1:2.7 nM |
| 体外活性 | PD-1/PD-L1-IN-10在体外以剂量依赖的方式显著促进了干扰素γ的分泌,即使在低浓度1 nM时也是如此[1]。PD-1/PD-L1-IN-10对LLC细胞和淋巴结T细胞的细胞活性没有影响[1]。PD-1/PD-L1-IN-10在小鼠Lewis肺癌(LLC)细胞中稳定了PD-L1蛋白的水平,并且特别地,PD-1/PD-L1-IN-10在58°C时以剂量依赖的方式维持了PD-L1的稳定性。这表明PD-1/PD-L1-IN-10可能进入LLC细胞后直接与PD-L1蛋白结合[1]。 |
| 体内活性 | PD-1/PD-L1-IN-10在LLC携带的同种异体移植小鼠模型中展现出强大的体内抗癌效果。PD-1/PD-L1-IN-10有效阻止肿瘤细胞的增殖,并在LLC肿瘤组织中诱导凋亡。[1] |
| 分子量 | 581.62 |
| 分子式 | C33H31N3O7 |
| CAS No. | 2487550-41-2 |
| Smiles | CC(O)[C@H](NCc1cc(c(OCc2cccc(c2C)-c2ccccc2)cc1OCc1cccc(c1)C#N)[N+]([O-])=O)C(O)=O |
| 密度 | 1.35 g/cm3 (Predicted) |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 100 mg/mL (171.93 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容